CHINESE and foreign researchers have jointly proven an innovative drug effective in treating moderate and severe ulcerative colitis, an inflammatory bowel disease (IBD), bringing a new treatment option.

As a group of chronic inflammatory diseases, IBDs mainly include ulcerative colitis and Crohn’s disease. They are prone to recurrent attacks, with pathogenesis not fully understood yet. Interleukin-6 (IL-6) is believed to be a key mediator of their pathogenesis.

The existing drugs have shown poor curative effects on IBDs, so the treatment strategy is to control symptoms and prevent their recurrence by suppressing overactive immune responses.

The innovative domestic drug, olamkicept, is a soluble fusion protein and can selectively inhibit the IL-6 trans-signaling. During its phase 2 clinical trials, a joint team led by researchers from the First Affiliated Hospital of Sun Yat-sen University (FAH), in collaboration with counterparts from 22 hospitals and research centers in East Asia, conducted a randomized, double-blind, and placebo-controlled study.

A total of 91 adult patients with active ulcerative colitis, with an average age of 41, were included in the study, starting from February 2018.

The results indicated that olamkicept with a dose of 600 milligrams showed a curative effect on patients with moderate and severe ulcerative colitis by significantly improving their clinical symptoms and biological indicators.

The research results have been published in The Journal of the American Medical Association (JAMA).(Xinhua)